Bariatric Fusion GLP-ONE+ Review 2026: It Doesn't Activate GLP-1 Receptors

Serving size 1 capsule, 30 servings per container. Directions: one capsule daily after a main meal — "Do not take on an empty stomach."

This is the central point, and it is a distinction worth carrying beyond this one product. Semaglutide is a GLP-1 receptor agonist. It binds the GLP-1 receptor directly and switches it on. That is what "receptor activator" means, and it is why the drug works whether or not your gut is producing any GLP-1 of its own. Bitter compounds do something different and upstream. They reach the intestine, activate bitter taste receptors (TAS2Rs) on the gut lining, and those receptors signal enteroendocrine cells to secrete your own GLP-1, along with CCK and PYY. The hormone then goes and activates the receptor. So the mechanism runs: bitter compound → bitter receptor → GLP-1 released → GLP-1 activates the GLP-1 receptor. The supplement acts at step one. It does not activate GLP-1 receptors. Naming it a "GLP-1 Receptor Activator" describes the drug's mechanism, not the botanical's — and it does so on a product explicitly positioned as working "without prescription injectables." The CB2 half of the claim, though, is correct, and we want to say so plainly because it is unusual for this category. β-caryophyllene is a genuine, well-characterised selective CB2 receptor agonist — established in a 2008 *PNAS* paper identifying it as a dietary cannabinoid, and confirmed repeatedly since. Copaiba really does contain it, and it really does activate CB2. The trouble is what CB2 activation does. CB2 is primarily an immune and anti-inflammatory receptor. The cannabinoid receptor that governs appetite is CB1 — which is why the anti-obesity drug rimonabant was a CB1 *blocker*, and why it was withdrawn over psychiatric side effects. Activating CB2 is not an established route to appetite suppression or weight loss in humans.

Hops genuinely has human appetite data, and it is some of the better evidence in this whole category. That is exactly why the mismatch matters. The studied ingredient is Amarasate®, a bitter hop flower extract. Randomised crossover trials — published in the *American Journal of Clinical Nutrition* and *Nutrients* — found it significantly decreased energy intake and increased CCK, PYY and GLP-1. It is a legitimate finding with a legitimate mechanism. Now compare the three things that made those trials work against what is in this capsule. 1. The compound is different. The Amarasate evidence is for a bitter extract — the bitter acids in hops are what activate bitter taste receptors. This product is standardised to xanthohumulone, a prenylated flavonoid. Xanthohumol has its own metabolic literature, but it is not the bitter principle, and the bitter-receptor mechanism is the entire basis of the appetite finding. 2. The dose is roughly an order of magnitude apart. The published trials used 100–500 mg of hop extract per day. This capsule provides 8 mg of its marker compound. Even reading it generously — 8 mg at ">15%" implies somewhere around 50 mg of extract — that is a fraction of the studied amount. 3. The delivery is the opposite design. This is the detail we find most telling. The trials used delayed-release capsules, engineered specifically to survive the stomach and release bitter compounds into the duodenum, because that is where the bitter receptors that trigger gut hormone release are. Getting the compound past the stomach is the whole technical problem those products exist to solve. This is a plain vegetarian capsule, and the directions say to take it after a main meal and not on an empty stomach — which is sensible for tolerability, and is close to the opposite of what the studied delivery method was trying to achieve.

While checking the standardisation, we found the hops figure stated three different ways — all on the same product page, on the same day.

Bariatric Fusion also publishes an article titled "Best Over-the-Counter GLP-1 Supplements to Support Your Health." It reads as a general buyer's guide to the category. Here is the order in which it presents the nutrients it recommends: 1. Copaiba (β-Caryophyllene). 2. Xanthohumulone. 3. Prebiotic Fiber (Sunfiber®, Solnul®). 4. Specialized Multivitamins for GLP-1 Users. Items one and two are precisely — and only — the two ingredients in Bariatric Fusion's own GLP-ONE+ capsule. Item four is a category Bariatric Fusion sells. We have now seen this pattern three times in this series, and it is worth naming as a pattern rather than an accusation against any one company. A vendor publishes an article in the format of an independent buyer's guide, optimised to be found by people searching for one, and the recommendations turn out to be the vendor's own catalogue. To be fair about our own position: Med Consumer Watch is an affiliate site and earns commissions on some products we review, which we disclose on every page that applies. The objection is not that a company has a commercial interest. It is that a roundup formatted as neutral guidance does not read as advertising to someone arriving from a search engine.

It is a low-stakes thing to try if: you are curious, $29.99 for a month is not a meaningful sum to you, and you understand you are testing a hypothesis rather than buying a demonstrated effect. There is no serious safety concern here — copaiba and hops are both well tolerated, the doses are modest, and the once-daily-with-food instruction is sensible. Buy the multivitamin instead if you are post-bariatric. This is the genuinely useful thing Bariatric Fusion makes. After sleeve gastrectomy, gastric bypass or duodenal switch, you need a purpose-built formulation and monitored bloodwork — B12, iron, calcium, vitamin D and the fat-soluble vitamins — and a generic multivitamin does not cover it. That product addresses a real, documented clinical need. This capsule does not. Skip it if: you are buying it expecting anything resembling a GLP-1 medication, because the name promises a mechanism the ingredients do not have; or you specifically want the bitter-hops appetite effect, in which case the dose, the compound and the delivery are all wrong and you should look for a delayed-release bitter extract at the studied dose. One practical caution. Hops has mild sedative properties — it is a traditional sleep botanical — so if you notice drowsiness, that is plausible rather than imagined. And if you take sedatives or drink alcohol, be aware of the potential for additive effect.

Does Bariatric Fusion GLP-ONE+ activate GLP-1 receptors? No. Bitter botanicals act upstream — they stimulate gut cells to secrete your own GLP-1 via bitter taste receptors. Activating the GLP-1 receptor directly is what prescription GLP-1 agonists like semaglutide do. The product's CB2 claim, however, is accurate: β-caryophyllene is a genuine selective CB2 agonist. What is in it? Two botanicals per capsule: copaiba extract 75 mg (10% β-caryophyllene) and xanthohumulone 8 mg from hops extract (>15%). Is the hops research real? Yes, and it is some of the better evidence in this category — but it is for a bitter hop extract (Amarasate) at 100–500 mg per day in delayed-release capsules, which significantly reduced energy intake and raised CCK, PYY and GLP-1. This product uses a different marker compound, at a much lower amount, in an immediate-release capsule taken with food. How much does it cost? $29.99 for 30 capsules, or $79.99 for 90 — about $1.00 a day, which makes it one of the cheaper products in this category. Why does the standardisation percentage differ across the page? We do not know. The description says 20%, a marketing image says 10%, and the supplement facts panel says ">15%." The supplement facts panel is the controlling document. Is Bariatric Fusion a legitimate company? Yes. Its core business is multivitamins formulated by bariatric practitioners for patients who have had ASMBS-endorsed procedures, which is a real clinical specialism. Our criticism is of this one product's claims, not of the company. Will it help me lose weight? There is no published trial of this finished product. The mechanism it invokes is real in principle, but the compound, dose and delivery here do not match the studies that established it. Are there side effects? Nothing serious is expected at these doses. Hops is mildly sedative, so drowsiness is plausible. Take it with food as directed. Can I take it with semaglutide or tirzepatide? There is no known dangerous interaction, but tell your prescriber. Adding an appetite product on top of a drug that already suppresses appetite risks inadequate intake, which is the main nutritional problem on these medications.